Economic evaluation alongside randomised controlled trials : design, conduct, analysis, and reporting by Petrou, Stavros & Gray, Alastair
 University of Warwick institutional repository: http://go.warwick.ac.uk/wrap 
This paper is made available online in accordance with 
publisher policies. Please scroll down to view the document 
itself. Please refer to the repository record for this item and our 
policy information available from the repository home page for 
further information. 
To see the final version of this paper please visit the publisher’s website. 
Access to the published version may require a subscription. 
Author(s):  Petrou, S. and Gray, A. 
Article Title: Economic evaluation alongside randomised controlled 
trials : design, conduct, analysis, and reporting 
Year of publication: 2011 
Link to published article:  
http://dx.doi.org/10.1136/bmj.d1548 
Publisher statement: © Petrou, S. and Gray, A. (2011). Economic 
evaluation alongside randomised controlled trials : design, conduct, 
analysis, and reporting. BMJ, 342, pp. d1548. This is an open-access 
article distributed under the terms of the Creative Commons 
Attribution Non-commercial License, which permits use, distribution, 
and reproduction in any medium, provided the original work is properly 
cited. 
Economic evaluation alongside randomised controlled
trials: design, conduct, analysis, and reporting
Collecting economic data at the same time as evidence of effectiveness maximises the information
available for analysis but requires proper consideration at the design stage
Stavros Petrou professor 1, Alastair Gray professor of health economics 2
1Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK; 2Health Economics Research Centre,
Department of Public Health, University of Oxford, Oxford, UK
Economic evaluation involves the comparative analysis of the
costs and consequences of alternative programmes or
interventions.1 It has increasingly been used to inform decision
making about healthcare in the United Kingdom and other
industrialised nations.2-5 Randomised controlled trials are
commonly used as a vehicle for economic evaluations. Indeed,
many funders, such as the UK National Institute for Health
Research Health Technology Assessment Programme, routinely
request that assessments of cost effectiveness are incorporated
in the design of randomised trials. This article outlines some of
the key issues concerning the design, conduct, analysis, and
reporting of economic evaluations based on trials with individual
patient data. Economic evaluations that synthesise data from
disparate sources using decision analytical models (typically
using summary rather than individual patient data) are discussed
in an accompanying article.6
What are the objectives of economic
evaluation?
Economic evaluations are typically concerned with two
quantities: the additional cost of a new treatment compared with
the existing alternative and the additional health benefits. If all
the costs and outcomes relevant to this comparison can be
measured, they can then be averaged across all patients in the
treatment (t) or the control (c) group to obtain mean cost C and
mean effect E for each group. It then becomes possible to
calculate a third quantity: the cost effectiveness of the new
treatment compared with the alternative. The incremental cost
effectiveness ratio (ICER) will simply be the difference in costs
divided by the difference in effects: ICER=Ct−Cc/Et−Ec=ΔC/ΔE.
This can be shown neatly on the cost effectiveness plane (fig).7
In the south east quadrant of the figure the new intervention is
less costly and more effective and (assuming there is no
uncertainty surrounding the cost effectiveness ratio) should be
adopted; equally, if the new intervention is less effective and
more costly (the north west quadrant), it can readily be rejected.
More controversially, new interventions may turn out to bemore
effective but also more costly (north east quadrant) or less
effective but also less costly (south west quadrant): in either
case, a trade-off then exists between effect and cost: additional
health benefit can be obtained but at higher cost, or costs can
be saved but only by giving up health benefit.
The question that then arises is whether the trade-off is
acceptable: is the health gain (or cost saving) worth the
additional cost (or health loss)? To address this question, we
can imagine a diagonal line running through the figure depicting
the maximum we are willing to pay for a unit of effect
(sometimes represented by the Greek letter λ). All points to the
right of this line involve a trade-off between costs and health
benefits that a decision maker might consider acceptable; while
all points to the left require an unacceptable trade-off. The
steeper the slope of this diagonal line, the more decision makers
are willing to pay for a unit of effect. There are various
techniques for estimating the value of λ.8 In many jurisdictions,
however, it has tended to reflect externally determined decision
rules that have evolved historically and with little scientific
basis.9 10 The point to note is that economic evaluation involves
two large uncertainties: where an intervention is located on the
cost effectiveness plane, and how much a decision maker is
willing to pay for health gains. Here we focus on the first
question, and consider the use of trial based economic
evaluations to obtain precise estimates of incremental cost
effectiveness.
Design of trial based economic
evaluations
Designing a rigorous trial based economic evaluation requires
close collaboration between trialists and health economists. This
collaboration should be reflected in the standard operating
procedures of the coordinating clinical trials unit, including its
data collection and informed consent procedures.11 Where
possible, the instruments and procedures used to collect
economic data should be pilot tested for efficiency, clarity, and
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ease of use.12 Pragmatic trials offer analysts an opportunity to
evaluate the cost effectiveness of an intervention under real
world conditions, with enrolled patients representative of typical
clinical caseloads, a comparison of the intervention of interest
with current practice, and follow-up under routine conditions.1
With less naturalistic trial designs, such as explanatory trials
designed primarily to answer questions about safety and
efficacy, the generalisability of the economic evaluation may
be impaired by stringent inclusion criteria and treatment
protocols or by the absence of a “usual care” arm.12 13 These
limitations are hard to overcome, although protocol driven costs
can and should be factored out of cost effectiveness
calculations.14
Although several techniques have been proposed to estimate
the appropriate sample size and statistical power for economic
end points in randomised trials,15-17 power calculations are almost
invariably based on primary clinical outcomes. This is partly
because of the complexity of trying to forecast the main outcome
of interest to economists—the joint distribution of the difference
in costs and benefits between treatment arms. Furthermore, large
sample sizes may be needed to detect statistically significant
differences because of the large variability in use of healthcare
resources and cost measures,18 and this may be neither
financially nor ethically acceptable.1 Economists therefore focus
on estimating cost and effect differences and assessing the
likelihood that an intervention is cost effective, rather than
testing a particular hypothesis concerning cost effectiveness.18
Some people might wonder whether an economic evaluation
should be included in a trial before we know whether the new
treatment is more effective. However, if it is not included we
risk losing the opportunity to collect information on use of
resources and health related quality of life. Furthermore, as
noted above, cost effectiveness is about the joint distribution of
differences in cost and effect. This joint distribution could show
clear cost effectiveness when neither cost nor effect differences
are individually significant. Indeed, some economists have
argued that reliance on traditional rules of statistical inference
surrounding a single parameter, such as clinical effectiveness,
is arbitrary and may result in inferior healthcare outcomes
comparedwith decisions based on expected cost effectiveness.1 19
How are data measured and valued?
Use of resources
The resources used by patients, such as hospital admissions,
consultations, and types and quantities of drugs administered,
are normally recorded for each patient over the trial follow-up.
The categories of resource use that are included in the study
will be determined by the perspective of the analysis—whether
it is confined to the healthcare system (sometimes referred to
as the payer) or includes broader societal costs. The system
perspective would typically include direct medical care,
including the intervention itself, treatment of any side effects
or complications, and follow-up care to the intervention or the
underlying condition. It may also include medical care not
directly associated with the underlying condition, although
regressionmodellingmay be required to disentangle background
noise that often occurs when this is included.20 In England and
Wales, the National Institute for Health and Clinical Excellence
(NICE) recommends includingNHS and personal social services
as a minimum.2The societal perspective also considers care
provided by other sectors of the economy, costs incurred by
patients, informal care provided by family and friends, and
productivity losses from morbidity and premature death.
Use of many resources can normally be recorded on trial case
report forms with little or no extra burden, but sometimes
additional information will be required from medical records,
patient questionnaires and diaries, and other sources.21A recent
trial based economic evaluation of neonatal extracorporeal
membrane oxygenation used observational research to estimate
resource use associated with complications and parental
questionnaires to document use of hospital and community
health services after discharge.22 Computerised record linkage
may in future simplify the process of collecting these additional
data.
When data are collected through patient or carer questionnaires,
researchers have to balance recall bias against completeness of
sampling information.23 Shorter recall periods of a few days or
weeks reduce the chance of a patient forgetting an episode or
incorrectly recalling when it occurred, but if a study is trying
to estimate resource use over a longer period, such as 12months,
sampling over a short recall period misses lots of data. It may
be better to maximise completeness at the cost of some recall
bias.24
Valuation of resource use
The total cost for an individual patient participating in a trial is
the product of the quantity of each resource item they use and
the unit cost of each item. Unit costs should theoretically be
based on the economic notion of opportunity cost, which
represents the value of the resource in its most highly valued
alternative use.1 In practice this is usually assumed to be
approximated by nationally representative healthcare tariffs,
such as the NHS payment by results tariffs25 or the diagnosis
related group payments in the USMedicare system.26However,
unit costs are not always readily available from such sources
andmay have to be calculated using a combination of accounting
data, time and motion studies, interviews with caregivers, and
case note analysis.
Standard unit costs are often applied across all patients and trial
centres, but non-standardised unit costs may be appropriate if
the relative prices of factors such as labour and equipment vary
between trial centres, especially in multinational trials.27 28 All
costs should be valued at the same price date, with adjustment
using healthcare specific inflation indices when necessary.29
Economic evaluations based on multinational trials should
convert costs into a common currency by using purchasing
power parity adjustments.30
Measurement and valuation of outcomes
Cost effectiveness may be reported in terms of many different
outcome measures, ranging from biomedical markers to more
final health outcomes.12 The preferred outcome measure for
many health economists, and many reimbursement agencies,
remains the quality adjusted life year (QALY), a preference
based measure of health outcome that combines length of life
and health related quality of life.31 For reimbursement agencies,
the QALY has the advantage of allowing cost effectiveness
comparisons between interventions for disparate health
conditions. For economists, the QALY offers the additional
advantage that it incorporates individual preferences for health
outcomes, therebymoving beyond the narrow biomedical model
for evaluative research.
To estimate QALYs patients typically complete at different
time points a generic health related quality of life questionnaire
with pre-existing preference weights that can be attached to
each health state—for example EQ-5D,32 the Health Utilities
Index,33 and the SF-6D.34 The underpinning preference weights
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for these measures are generally drawn from surveys of the
general population, and so descriptive data from patients are
combined with health related quality of life weights (or utility
scores) from the general population and survival data from the
trial to generate QALY profiles. An alternative approach is to
ask patients not only to describe their health status but also to
value it using a complex scaling technique such as the standard
gamble approach or time trade-off approach.35 These techniques
are more expensive and time consuming than using population
weighting. For both approaches, the frequency and timing of
assessments should be influenced by disease severity, speed of
progression, and the questionnaire burden on patients.36 When
patients are too ill or do not have the cognitive competencies
to complete a questionnaire, proxy measurements may be
considered.37
If a trial has not included a quality of life assessment, mapping
techniques can sometimes be used to predict preference based
health related quality of life (or utility) scores based on responses
to non-preference based measures.38 This requires data from a
separate study where both the preference based and
non-preference based measures were completed. For example,
Williamson and colleagues used data from a study that
developed a utility algorithm for the OM8-30 otitis media with
effusion questionnaire39 to predict preference based health related
quality of life scores, and consequently QALYs, for children
participating in a randomised trial of topical intranasal
corticosteroids for persistent bilateral otitis media with
effusion.40
The QALY may be considered too restrictive or insensitive to
the main outcomes of interest in some circumstances.
Researchers are therefore developing instruments that try to
measure broader outcomes such as attachment, security,
enjoyment, role, and control that can still be used within an
economic evaluation framework.41
Analysis and reporting of data
Discounting
Trial based economic evaluations often measure and value costs
and outcomes over several years of patient follow-up. In this
situation costs and outcomes that occur after the first year of
follow-up are typically reduced by a discount factor so that they
can be fairly compared. Some economists have argued for
applying different discount rates to future costs and health
outcomes,42 but NICE recommends that economic evaluations
conducted in England and Wales should discount both costs
and outcomes at an annual rate of 3.5%.2 Sensitivity analyses
that test the effects of differential discount rates on costs and
outcomes are recommended.2
Dealing with skewed, missing, and censored
data
The costs and outcomes of the trial groups, and the respective
differences between them, can be summarised in several ways.
For costs, the crucial information is usually the arithmetic
mean—that is, average cost—as this allows policy makers to
estimate the total cost of implementing a programme or
intervention.43Although cost data are often right skewed because
a few patients use very high amounts of resource, producing a
distribution that may violate the assumptions of standard
statistical tests, it is not clear that the many alternative
approaches suggested, such as bootstrapping, provide more
reliable test results.44 Indeed, simple approaches for analysing
cost data that assume normal distributions may be preferable in
large samples where the near-normality of sample means is
assured, while relatively simple approaches, such as generalised
linear models, may be sufficient in smaller samples to deal with
problems such as skewness and excess zeros.44 For clinical
outcomes, it is generally most transparent to replicate the
methods of the primary clinical analysis plan to summarise
outcomes. Note, however, that economists will be interested in
all events, whereas trialists may be more interested in time to
the first event. For QALYs, it may be important to adjust for
baseline differences in health status between the trial groups.45
Missing data are a particular problem for economic evaluations
alongside trials, as the analysis may be drawing on information
from case report forms, adverse event data, medication files,
health related quality of life and resource use questionnaires,
and other sources at all points across the study. The problem
may be mitigated, in part, by approaches such as postal or
telephone reminders to patients. Nevertheless, a complete case
approach might require that most patients are dropped and is
seldom a realistic option. Instead, analysts increasingly favour
multiple imputation, where multivariate regression techniques
are used to predict missing values on the basis of existing data.46
The precise approach will depend on the nature of the missing
data: (i) missing completely at random, with no relation to the
value of any other factors in the study population; (ii) missing
at random, but correlated in an observable way with the
mechanism that generates the outcome; and (iii) not missing at
random, but dependent on unobserved variables.46 A particular
form of missing data is censoring, where information on some
patients is truncated and not available for the full duration of
interest. In the past, analysts often ignored the effects of
censoring on the estimation of costs and outcomes, but survival
analysis methods are increasingly being used to deal with this
problem.8
Handling uncertainty
As we noted when discussing the cost effectiveness plane, trial
based economic evaluations result in different types of
uncertainty. Sampling (or stochastic) uncertainty, usually
reported as a confidence interval, depends on variation in both
the numerator (incremental cost) and the denominator
(incremental effectiveness) of the incremental cost effectiveness
ratio. However, ratios are difficult statistics to work with: in
cost effectiveness ratios the denominator (the effect difference)
may be zero, producing an intractable result. Another problem
is that the same negative value might represent improved
outcomes and lower costs or worse outcomes and higher costs.
This makes confidence intervals hard to compute and to
interpret.
An alternative is to assume that the decisionmaker’s willingness
to pay for health gain is known and then rearrange the ratio on
a linear scale to see whether the intervention produces any net
benefit. For example, if the actual health benefits produced by
the intervention are multiplied by the assumed willingness to
pay for these benefits, and the net costs are subtracted, we
produce a linear scale where a negative is unambiguously bad
(the costs outweigh the value placed on the health benefits) and
larger benefits are unambiguously better.47 This net benefit
approach makes it straightforward to examine decision
uncertainty—that is, uncertainty over the value of the
willingness to pay for health gain (λ)—by assessing the
probability that the new intervention is cost effective across a
range of values of λ. This is often displayed as a cost
effectiveness acceptability curve.48
Heterogeneity in the trial population could also be explored by
formulating a net benefit value for each patient from the
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observed costs and effects, and then constructing a regression
model with a treatment variable and covariates such as age, sex,
and disease severity. The magnitude and significance of the
coefficients on the interaction between the covariates and the
treatment variable might then provide an estimate of cost
effectiveness by subgroup. Finally, methodological uncertainty,
the uncertainty concerning issues such as the appropriate
discount rate or cost perspective, can be explored by standard
sensitivity analyses.
Longer term extrapolation
Cost effectiveness observed within a trial may be substantially
different from what would have been observed with continued
patient follow-up: for example, the benefits of reducing fatal
outcomes typically continue well beyond the end of the trial.
Consequently, extrapolation of cost effectiveness over an
extended period, often a lifetime, is considered important.36 49
Survival analysis models, such as the Cox proportional hazard
model or Weibull model, are often used to estimate life
expectancy with and without an intervention.50 However,
unbiased estimation of long term cost effectiveness may require
more complex models of the disease process, accompanied by
related information on the cost and utility of interventions and
complications.
Trial based economic evaluations that use patient level data
have important advantages in permitting the construction of
such models and permitting them to be validated. A good
example comes from the UK Prospective Diabetes Study.51 The
trial followed up patients for a median of 10 years. However,
the wealth of individual patient data permitted the construction
of a model consisting of a set of linked equations that predict
the risks of major diabetes related complications, and this has
been used to estimate the lifetime costs, utilities, and cost
effectiveness of diabetes related interventions.52 The interactions
within the model between risk factors, individual characteristics,
and disease history could not have been captured reliably
without access to patient level data.
Advantages of trial based economic
evaluations?
Economic evaluations conducted alongside randomised
controlled trials provide an early opportunity to produce reliable
estimates of cost effectiveness at low marginal cost. Access to
individual patient data also permits a wide range of statistical
and econometric techniques—for example, to examine the
relation between events of interest and health related quality of
life or to explore subgroup differences. Although trial based
evaluations have limitations—truncated time horizons, limited
comparators, restricted generalisability to different settings or
countries, and the failure to incorporate all relevant
evidence53—they are likely to continue to have an important
role in producing reliable estimates of cost effectiveness.
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Summary points
Economic evaluation is increasingly used to inform the regulatory and reimbursement decisions of government agencies
Evaluations conducted alongside randomised controlled trials provide access to data on individual patients
This enables a wide range of analytical techniques—for example, to examine the relation between events of interest
and health related quality of life
Designing a rigorous trial based economic evaluation requires close collaboration between trialists and health economists
from the outset of the trial
Key issues concerning the design, conduct, analysis, and reporting of economic evaluations based on randomised trial
with individual patient data are outlined
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Figure
The cost effectiveness plane. The x axis shows the difference in effectiveness between the new treatment and the comparator
and the y axis shows the difference in cost. The slope of the line from any point on the figure to the origin is the incremental
cost effectiveness ratio
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